2024
Hypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma
Yang Z, Chen Q, Dong S, Xu P, Zheng W, Mao Z, Qian C, Zheng X, Dai L, Wang C, Shi H, Li J, Yuan J, Yu W, Xu C. Hypermethylated TAGMe as a universal-cancer-only methylation marker and its application in diagnosis and recurrence monitoring of urothelial carcinoma. Journal Of Translational Medicine 2024, 22: 608. PMID: 38956589, PMCID: PMC11218302, DOI: 10.1186/s12967-024-05420-3.Peer-Reviewed Original ResearchConceptsRecurrence monitoringMethodsThe methylation levelsIndicator of recurrenceBackgroundUrothelial carcinomaClinical recurrenceUrothelial carcinomaBenign diseaseUrological malignanciesPostoperative surveillanceUC diagnosisUC patientsTraining cohortUrothelial markersValidation cohortRecurrenceClinical scenariosUrinary systemClinical utilityCarcinomaMethylation markersPatientsUrine samplesTissue samplesUrineDiagnosis
2020
The human microbiome and genitourinary malignancies
Nicolaro M, Portal D, Shinder B, Patel H, Singer E. The human microbiome and genitourinary malignancies. Annals Of Translational Medicine 2020, 8: 1245. PMID: 33178777, PMCID: PMC7607065, DOI: 10.21037/atm-20-2976.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsImmune checkpoint inhibitorsTyrosine kinase inhibitorsGenitourinary malignanciesResponse to certain drugsCheckpoint inhibitorsPredictors of diseaseOncological outcomesEffects of antibioticsProstate cancerMicrobial signaturesUrological malignanciesEtiology of disease statesTreatment coursePrognostic indicatorBladder cancerSystemic inflammationHealthy patientsUrinary microbiomeKidney cancerKinase inhibitorsMalignancyGenitourinary diseasesHuman microbiomeTherapeutic targetCancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply